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Treatment of rat mesangial cells with interleukin-lp (IL-Ifl) and forskolin induced, in a synergistic fashion, the expression ofgroup II phospholipase 
AZ (PLA,) mRNA, with subsequent increased synthesis and secretion of PLA.. In contrast, interlcukin-6 did not increase PLAz mRNA levels of 
PLA: acivity. Transforming rowth factor (TGF) p,, TGF@, and TGFP, equipotcntly attenuated the ft.Ia- and forskolin-induced elevation of 
PLA: mRNA, as well as PLA. synthesis and secretion. The glucocorticoid examethasone only partially suppressed the IL-lp- and forskolin- 
induced elevation of PLAl mRNA, but totally inhibited PLA* synthesis and secretion. 
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1. INTRODUCTION 
IL-l is a polypeptide mediator that was originally 
reported as a secretory product of activated macroph- 
ages but later on was found to be produced by a variety 
of cell types [I], including mesangial cells [2,3]. IL-l is 
a central factor in the pathogenesis of immune and in- 
flammatory processes [I]. We and others have previ- 
ously demonstrated that lL-1 induces prostaglandin EZ 
14-61 and group II PLA? [4,73 synthesis in mesangial 
cells. PLAl catalyses the release of arachidonic acid 
from the sn-2 position of phospholipids, thereby initiat- 
ing the synthesis of eicosanoids which profoundly mod- 
ulate inflammatory processes. Evidence to date suggests 
that PLA+ are a heterogeneous family of enzymes that 
can be classified into two classes. A class of high molec- 
ular weight PLA,s of 60-l 10 kDa, a!so referred to as 
cytosolic PLA+ or cPLA?s, and a class of low molecular 
weight PLA,s of 14 kDa referred to as secretory PLA2s 
or sPLA+. Members of both classes from human and 
rat sources have recently been cloned [S-13]. The 
sPLA,s are further classified into two groups, based on 
their primary structure [14]. Mammalian group I PLAl 
comprises the pancreatic type of PLA? and mammalian 
group 11 PLAl is synthesized and secreted from many 
cell types and is believed to play a role in the initiation 
and propagation of inflammatory processes ( ee [1 S] for 
review). In addition to IL-l and tumour necrosis factor 
a (TNFa), which have been shown to activate group II 
PLA? synthesis in a variety of cell types [151, Crowi and 
colleagues [ 161 observed a stimulating action of inter- 
leukin-6 on PLA? gene expression in human hepatoma 
cells. We were the first to report an increased secretion 
of PLAl from vascular smooth muscle cells [17] and 
mesa&al cells [l&19] in response to agents that in- 
crease cellular levels of CAMP, such as forskolin. Fur- 
thermore, IL-ID and TNFa synergistically interact with 
forskolin to stimulate PLA? release from vascular 
smooth muscle [20] and glomerular mesangial cells 
[l&19]. Both forskolin-stimulated and cytokine-stimu- 
lated PLA? synthesis and secretion is dose-dependently 
prevented by pretreatment of cells with dexamethasone 
[21-231, TGF& 124,251 and platelet-derived growth fac- 
tor [26]. 
In this report, we present evidence that IL-lb and 
forskolin synergistically increase group II PLA2. mRNA 
levels in mesangial cells, whereas interleukin-6 shows no 
effect. Dexamethasone and the three members of the 
mammalian TGF,8 family partially attenuate the stimu- 
latory action of IL-lb and forskolin on PLAZ mRNA 
levels. 
Abbreviu~ions: PLA:, phospholipase AZ; IL-I, interleukin-I; TNF, tu- 
mour necrosis factor; TGF, transforming rowth factor, 
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2. MATERIALS AND METHODS 
2. I, Cell c~rlfures und irw4boriott 
Rat mcsangiai cells were cultured, c!oned and characterized as de- 
scribed previously [26,27]. The cells were gor.vn in RPM1 1640 supple- 
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mentecl with 10% fetal calf serum, penicillin (100 U/ml), streptomycin land); adenosinc 5’-[y-“Pltriphosphate (spaific activity *l IO TBq/ 
(100 pdrnl) and bovine insulin at 0.66 U/ml. For the experiments mM) was purchased from Amersham International (UK); forskolin 
passages 1 S-37 ofmesangial cells were used. Confluent mesangial cells was from Calbiochem (Luoxnc , S:?3!&md); recombinant human 
cultured in 16 mm diameter wells were washed twice with PBS and IL-la. recombinant human TCIFflz and TGFB, were prepared by the 
incubated with I ml of RPM1 1640, containing 0.1 mg/ml of fatty Biotechnology Department of Ciba-Geigy Ltd (BaseI. Switzerland). 
acid-free bovine serum albumin (Sigma) with or without agents for the recombinant human interlcukin-6 and human TGFB, were from Brit- 
indicated time periods. Thereafter, the medium was withdrawn and ish Bio-technology, Oxford, UK; T4-polynucleotidc kinase and all cell 
centrifuged for 10 min at 1000 rpm in an IEC Ccntra-7R lab centri- culfurc nutrients were from Boehrlnger-Mannhcim (Germany), and 
fuge. The supernatant was rcmovbti and frozen in liquid nitrogen and all other ctcmicals used were from cithor Merck (Darmstadt, Ger- 
stored until assayed for protein content and PI-A, activity. many) or Fluka (Buchs, Switzerland). 
2.2. Pifosphoiipase A2 assay 
PLAz activity was detem~ined using [I -“‘C]oleate-labelled E. co/i as 
substrate as described [28]. Assay mixtures (1.0 ml)contained 100 mM 
Tris-HCI (pH 7.4), I.0 mM CaCI:, 5 nM E. coli phospholipid (3000- 
SWOcpm) and the enzyme to be tested at a dilution producing approx- 
imately 5% substrate hydrolysis. Reactions were stopped after 1 h and 
the liberated [“C]olcate was extracted by a modified Dolt extraction 
procedure [28]. 
3. RESULTS 
2,3. Nortkent blot atudysis 
Confluent mcsangial cells were harvested from 60 mm diameter 
culture dishes with a rubber policeman. Total RNA was extracted 
from the cells using the guanidinium thiocyanatc/phenol/chloroform 
method [29]. The RNA was precipitated and samples of I5 pg RNA 
were separated on 1% aLarose gels containing 6.6% formaldehyde, 
prior to transfer to Gene Screen membranes (New England Nuclear) 
[JO]. After baking the filters at 80°C for 2 h and prehybridization for 
6 h, the filters were hybridized with a 39-mer antisensc oligonucleotids 
for rat group II PLA! (nccleotide 58-96, [lo]), that bad been labelled 
with T4-polynucleotidc kinase and [y-“P]ATP [30]. To correct for 
variations in RNA amount a parallel Alter was hybridized with a 
genomic lone for rat 28 S ribosomal RNA [31], labcllcd with the 
random primer technique described by Feinbcrg and Vogclstein [32]. 
After hybridization, the membrane war washed 3 times in 4 x SSPE, 
0.1% sodium dodecyl sulfate at 50°C for 20 min (20 x SSPE: 3.6 M 
sodium chloride, 0.2 M sodium phosphate, 0.02 M EDTA. pH 7.4). 
The signal was detected by autoradiogrdphy. 
[I-lJC]Oleic acid and nylon membranes (Gene Screen) were pur- 
chased from DuPont de Nemours International (Regcnsdorf’. Switeer- 
Northern blot analysis using an oligonucleotide 
probe for group II PLA2 revealed that IL-lp dose-de- 
pendently increased the amount of group II PLAl 
mRNA (Fig. 1) which was accompanied by an enhanced 
secretion of PLAz into the culture supernatant, as mon- 
itored by PLA2 activity measurements (Table I). Fig. 2 
shows that while IL-l@ (lane 2) and forskolin (lane 4) 
alone induced only a modest increase in PLAz mRNA, 
when given together they evoked a strong synergistic 
response on PLAl mRNA levels (lane 3) and PLA2 
activity (Table I). In contrast, interleukin-6 had no ef- 
fect on either PLA2 mRNA levels (Fig. 2, lane 5) or 
PLAz activity (Table I). Next we examined the effects 
of dcxamethasone and TGFp2 on IL-l/?- and forskolin- 
stimulated PLA2 gene expression. As shown in Fig. 3, 
dexamethasone and TGF& dose-dependently antago- 
nized IL-lb plus forskolin-induced PLAz mRNA accu- 
mulation. All three of the human TCiFjl isoforms dis- 
played a comparable potent inhibitory action on cyto- 
kine- and forskolin-stimulated PLAz mRNA accumula- 
tion (Fig. 4). Whereas the inhibitory effkcts of TGFB,, 
TGIF,& and TGFpJ on mRNA levels (Figs. 3 and 4) 
were closely paralleled by the PLA2 activity measure- 
Table I 
Effects of TGFs type-,!7 and interlcukin-6 on IL-lg and forskolin-stimulated PLAl secretion from mesangial ceils 
Addition PLA. secretiou 
(CP~l~ Ul) 
Control 260 ?: 14 
IL-lj8 (I nM) 14645 41 
Forskolin (l0~1M) IS15f 92 
IL-ID (1 nM) + Forskolin (IO PM) 6834 + 201 
Interleukin-b (18 ng/ml) 285 + 21 
IL-IF (I nM) + Forskolin (IO PM) + TGFB, (1 Wml) 613b r? 254 
IL-I/3 (I nM) + Forskolin (IO PM) + TGF/9, (IO ndml) 3754 f 184 
IL-l/9 (I nM) + Forskolin (IO PM) + TGF/9, (30 @ml) 2454 f 122 
IL-l/!3 (1 nM) + Forskolin (lo PM) * TGFpz (1 @ml) 6015 f 193 
IL-If5 (1 nM) + Forskolin (IO PM) + TGFp2 (IO ng/ml) 3598 f 144 
IL-l/l (1 nM) + Forskolin (1OyM) + TGFB, (30 @ml) 2198 -+ 135 
IL-IS (I nM) + Forskoliu (IO PM) + TGFB, (i nS/ml) 5981 2 239 
IL-l/3 (I nM) + Forskolin (10 PM) + TGF/$ (IO ng/ml) 3618 f 204 
IL-l/7 (1 nM) + Forskolin (10 PM) f TGFj9, (30 ndml) 2085 f 9s 
IL-l/t (1 nM), + Forskolin (IOyM) + Dexamcthasonc (IO IIM) 3441 & 118 
IL-&8 (1 l\M) + Forskolin (IO PM) + Ccxamcthasonc (!O yM) 190+ I2 
Control mesangial cells were incubated with the indicated concentrations of IL-l,& Forskolin, TGF/?,. TGF&.TGF& 
or Dexamethasone for 24 h. Thereafter, the medium was withdrawn and PLA: activity determined as described in 
section 2. Results are means f SE (n = 4). 
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Fig. I. Dose-dependent accumulation of group II PLAz mRNA in 
IL-l~&imulatecI mrsangial cells. Mesangial cells were incubated with 
vehicIe(control) (I), or IL-lp 100 pM (2), 500 pM (3), I nM (4),5 dM 
(5) and IO nM (6) for 20 h. Cellular RNA (IS pg) was analyzed by 
Northern blotting as described in section 2. 
ments (Table I), showing a 60-708 suppression at the for the induction of sPLA2, one is activated by CAMP 
highest concentrations used, the inhibitory action of and the other is triggered by IL-l, and uses a signalling 
dexamethasone was strikingly more pronounced at the pathway different from i he adenylate cyclase system. In 
PLAl activity values (Table I) as compared to the PLA? contrast, interleukin-6 which has been shown to induce 
mRN.4 levels (Fig. 3). At the highest concentration of group II PLAl gene expression in human hepatoma 
dcxamethasone used (10 PM), PLAz mRNA was re- cells [16], has no ef?‘ect on PLA, gene expression in 
duced by approximately 708, whereas a 100% inhibi- mesangial cells. thus displaying a more restricted cell 
tion of secreted PLA? activity was determined. and tissue selectivity than IL-1 or TNFa, 
4. DISCUSSION 
IL-la, IL- I/?, and TNFol as well as CAMP-elevating 
compounds have been shown to induce the synthesis 
and release of group II PLAz into the medium of cul- 
tured rat glomerular mesangial cells [4,7,17-193. The lag 
period of several hours before the onset of PLAz secre- 
tion and the inhibition by actinomycin D and cyclo- 
heximide indicated the involvement of RNA synthesis 
and protein synthesis in these processes. Recently we 
and others have shown that IL-1 and forskolin indeed 
stimulate group II PLA, gene expression in mesangial 
cells [26,33]. In the present report we have extended our 
studies and demonstrate that IL-IS dose-dependently 
increases PLAl mRNA levels in mesangial cells. Fur- 
thermore, we show that forskolin synergistically inter- 
acts with IL-l/3 to increase group II PLA? mRNA accu- 
mulation, thus confirming our previous data based on 
activity measurements [18,19]. These data suggest hat 
there exist at least two distinct activation mechanisms 
Fig. 2. Synergistic stimulation of group II PLAl mRNA levels in 
dxA2 
+28S rRNA 
mesangial cells trcatcd with IL-l,!3 and fcrskolin. ??Iexqial cells were 
incubated with vehicle (control) (I), IL-@ (5 nM) (Z), forskolin (IO 
yM) (4); IL-I/I (S nM) plus forskolin (IOyM) (3) or interleukind, (I8 
ns/ml) (5) for 20 h. Cellular RNA (I5 yg) was analyzed by Northern 
Fig. 4. Effect of the different TGFP isotypes on &oup II PLA, mRNA 
levels in stimulated mesrtnglal cells. Mer;angial cells were incubated 
with vehicle (control)(S), IL-l/3 (IO nM)plus ‘. .s :.olin (IOpM) alone 
(4) or in combination with 30 n&ml TGFj, (JJ, 30 n&/ml TGFbz (2) 
or 30 ng/ml TGFpI (I j for 20 II. Cellular RNA (15 ,Q was analyzed 
blotting as described in section 2. by Northern blotting as described in section 2. 
1 234567 
Fig. 3. Effect of TGFB; and dexamethasonc on group II PLAI mRNA 
levels in stimulated mesangial cells. Mesangial cells were incubated 
with vehicle (control) (7), IL-IpI (IO nM)plus forskolin (10jfM) alone 
(3) or in combination with TGFB, 1 ndml(4), IO ng/ml(5), 30 @ml 
(6), or in combination with dexamethasonc IOnh! (I) or IO yM (2) 
for 20 h. Cellular RNA (I5 &I) was analyzed by Northern blotting as 
described in section 2. 
TGF,B is a 25 kDa dimeric peptide, which exerts di- 
verse actions on many cells, ranging from growth pro- 
motion to growth inhibition and immunomodulation 
(for review see [34,35]). TGFB has been purified from 
normal kidney [36], and the presence of high-affinity 
receptors for TGF/J on mesangial cells has been re- 
ported [37]. It is now known that TGFB belongs to a 
family of closely homologous dimeric proteins. Three 
distinct forms OF TGFj3 have been described in mam- 
mals and were designated as TGF&, TGF/& and 
TGFj& [34,35]. We have previously shown that TGFbz 
strongly inhibits PLAz secretion from mesangial cells 
induced by IL-I or tumour necrosis factor [24,25], In 
the present report, we demonstrate for the first time the 
potent inhibition of IL-lb- and forskolin-induced PLAl 
gene expression by all three human TGFP isoforms 
(Figs. 3 and 4). This inhibitory action of TGF;B,, TGFbz, 
and TGFpJ is also evident From the marked reduction 
of PLA? activity (Table I) in the culture supernatant of 
stimulated mesangial cells. In this respect all three 
isotypes of TGF,5 displayed an equally potent inhib- 
I +PLA2 
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itory profile on PLA? mRNA levels and PLAz activity 
(Fig, 4 and Table I). 
The glucocortiwid inhibition of PLA2 was initially 
attributed to the production of the PLAz inhibitor pro- 
tein lipocortin [38]. However, recent reports have ques- 
tioned the role of lipocortin as a biologically relevant 
PLAz inhibitor, in that inhibition of PLA2 by Iipocortin 
in vitro was only observed at very low substrate concen- 
trations and was due to substrate sequestration, rather 
than to direct PLA,-lipocortin interaction [39,40]. Fur- 
thermore, several reports described lipocortin-inde- 
pendent inhibition of PLA? activities and eicosanoid 
synthesis [41-&l]. We and others have shown that dex- 
amethasone treatment inhibits the cytokine- and for- 
skolin-stimulated synthesis and secretion of group i1 
PLA? from mesangial cells [21,23] and smooth muscle 
cells [22], thus providing an alternative xplanation for 
the potent inhibition of eicosanoid mediator synthesis 
by glucocorticoids. In the present report we describe 
that dexamethasone partially suppresses IL-l/S and 
forskolin-stimulated levation of group II PLAz mRNA 
levels (Fig. 3). At the highest concentration of dexa- 
methasone used (IO yM), there was only a 70% reduc- 
tion of PLAz mRNA levels. In contrast, PLA? synthesis 
and secretion were completely prevented by treatment 
of the cells with such a high concentration of dexameth- 
asone (Table I and [23]). We have observed that the 
inhibition of PLAl activity in both culture media and 
cells is paralleled by decreases in PLAl mass [23]. This 
indicates that dexamethasone inhibits not only secretion 
of induced PLA,, with accumulation of PLA? protein in 
the cells, but inhibits PLA, protein synthesis. Further- 
more, this also excludes an increased reuptake of se- 
creted PLAz back into the cells. These data observed in 
rat mesangial cells confirm a recent report [22] describ- 
ing the action of dexamethasone on group II PLALI 
expression in vascular smooth muscle cells. TNFa-in- 
duced PLA3 mRNA accumulation was less affected 
compared to the severe suppression of PLA, protein 
and activity, suggesting that glucocorticoids can also 
inhibit PLA, expression at a posttranscriptional level 
[22]. Measurement of PLA? mRNA stability and in 
vitro translation of PLAl mRNA would be an impor- 
tant next step in elucidating the effect of dexamethasone 
on lL-I/3- and forskolin-induced group II PL& expres- 
sion. 
There is substantial evidence that extracellular group 
II PLA? plays an important role in the pathogenesis of
diverse inflammatory processes [15]. The selective inhi- 
bition of cytokine induction of group II PLAz may be- 
come a useful therapeutic approach to the treatment of 
these diseases. Glucocorticoids ‘nave already proven to 
exert beneficial effects on inflammatory reaction in a 
variety of organs, including the kidney [45]. The inhibi- 
tion of IL-1 and TFNor induction of group II PLAl in 
mesangial ce1l.s may be one aspect of this curative gluco- 
corticoid action seen in certain renal diseases. Anti- 
inflammatory steroids may act in line with TGFB 
[24,46] and platelet-derived growth factor [26] to protect 
the kidney from damage resulting from IL-l- and 
TNFor-induced mediator secretion and subsequent in- 
flammatory reactions. 
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